

Alzheimer's disease: Time to reassess research and clinical priorities

Benita Wiatrak^{A–F}, Adam Szeląg^{E,F}

Department of Pharmacology, Faculty of Medicine, Wrocław Medical University, Poland

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation; D – writing the article; E – critical revision of the article; F – final approval of the article

Advances in Clinical and Experimental Medicine, ISSN 1899–5276 (print), ISSN 2451–2680 (online)

Adv Clin Exp Med. 2026;35(3):397–401

Address for correspondence

Benita Wiatrak
E-mail: benita.wiatrak@umw.edu.pl

Funding sources

None declared

Conflict of interest

None declared

Received on November 5, 2025

Reviewed on December 15, 2025

Accepted on January 21, 2026

Published online on February 4, 2026

Abstract

Alzheimer's disease (AD) remains one of the most pressing challenges in contemporary neurology, with growing evidence highlighting the limitations of the amyloid hypothesis and monomodal therapies. This editorial advocates for a shift toward multidimensional research and therapeutic frameworks that integrate molecular, electrophysiological, neuroimaging, and behavioral data. Emphasis is placed on the potential of microRNA-based biomarkers, electroencephalography (EEG) analysis, and non-invasive methods to improve early diagnosis. Emerging multimodal treatment strategies – including immunotherapy, neurostimulation, and nutraceuticals – are discussed alongside ethical and regulatory challenges in implementing novel interventions. The authors propose an integrated, patient-centered model that combines precision medicine with preventive approaches rooted in lifestyle, digital biomarkers, and AI-powered personalization. A paradigm shift toward systemic, translational, and ethically grounded strategies is urgently needed to meet the growing burden of AD.

Key words: biomarkers, Alzheimer's disease, multimodal therapy, amyloid hypothesis

Cite as

Wiatrak B, Szeląg A. Alzheimer's disease: Time to reassess research and clinical priorities. *Adv Clin Exp Med.* 2026;35(3):397–401. doi:10.17219/acem/217199

DOI

10.17219/acem/217199

Copyright

Copyright by Author(s)

This is an article distributed under the terms of the Creative Commons Attribution 3.0 Unported (CC BY 3.0) (<https://creativecommons.org/licenses/by/3.0/>)

Highlights

- Limitations of the amyloid hypothesis underscore the need for multimodal and system-level approaches to Alzheimer's disease (AD) diagnosis and treatment.
- Integrating microRNA biomarkers, EEG analysis, neuroimaging, and behavioral data may significantly enhance early and accurate AD detection.
- Emerging multimodal therapies – including immunotherapy, neurostimulation, and nutraceuticals – offer new avenues beyond monomodal treatment strategies.
- A patient-centered, AI-driven precision medicine framework is proposed to address AD through prevention, personalization, and ethical translational research.

Introduction: Therapeutic stagnation and unanswered questions

Alzheimer's disease (AD) remains one of the most urgent challenges in modern neurology and public health. The number of affected individuals worldwide now exceeds 55 million, and World Health Organization (WHO) projections suggest that this figure could double by 2050, reaching up to 139 million. This trend is particularly alarming in the context of global population aging. Every day, new cases of dementia are diagnosed, with AD representing the most common cause. As life expectancy increases, the burden on healthcare systems and families also grows, with substantial economic and emotional consequences.^{1–4}

Despite decades of intensive research and massive investments from both the public and private sectors, there is still no therapy available that effectively modifies the course of the disease. Existing medications are symptomatic and offer only modest and temporary benefits. In recent years, the highest hopes were pinned on monoclonal antibodies targeting β -amyloid; however, the results of clinical trials have proven disappointing.⁵

Although some of these therapies, such as aducanumab, lecanemab, and donanemab, have been approved by the U.S. Food and Drug Administration (FDA), they are accompanied by controversies regarding both their limited clinical benefit and potentially serious side effects, including brain edema and microhemorrhages.^{5,6}

In this context, the need for a fundamental reassessment of the prevailing approach is increasingly evident; a redefinition of research priorities, efficacy and safety criteria, and the pursuit of new, more complex models of pathogenesis and therapy are urgently needed.

A critical look at the amyloid hypothesis

For more than 3 decades, the amyloid hypothesis has served as the dominant framework for AD research.⁷

It posits that the pathological accumulation of β -amyloid ($A\beta$) in the brain initiates a cascade of events leading to neurodegeneration: from plaque formation to oxidative stress, inflammation, and ultimately neuronal death. Based on this concept, dozens of therapeutic strategies have been developed – primarily monoclonal antibodies, secretase inhibitors, and active or passive immunotherapies.⁸

However, with the exception of rare early-onset cases, growing evidence challenges the causal role of $A\beta$ in typical AD. First, neuropathological data show that the presence of plaques does not consistently correlate with cognitive impairment.⁹ Second, many older individuals with high amyloid levels remain clinically asymptomatic. Third, randomized clinical trials (RCTs) have demonstrated that amyloid clearance from the brain does not translate into meaningful cognitive improvement.¹⁰

Neuroinflammation, the microbiome, and other pathogenetic pathways

In light of the increasing number of negative results from anti-amyloid therapies, the scientific community is turning its attention to alternative or complementary mechanisms of AD pathogenesis. In recent years, particular importance has been assigned to neuroinflammation, microglial activation, and disruptions in immune homeostasis. The inflammatory response in the central nervous system, once considered secondary, may in fact play a triggering or co-contributing role in disease progression.

A more complete account of AD pathobiology also requires acknowledging additional hypotheses that are not merely “alternatives” to amyloid, but often intersect with it. The tau hypothesis emphasizes the abnormal phosphorylation, misfolding, and spread of tau pathology, culminating in neurofibrillary tangle formation and network disintegration.¹¹ Importantly, tau burden and topography frequently show a closer association with clinical progression than amyloid deposition alone,¹² suggesting

that amyloid-centered strategies may be insufficient if downstream neurodegenerative processes are already established.

In parallel, neurotransmitter and network-level hypotheses provide mechanistic bridges between molecular pathology and symptoms. Glutamatergic dysfunction – including impaired synaptic homeostasis and excitotoxic signaling – can contribute to synapse loss and circuit instability,¹³ aligning with emerging interest in electroencephalography (EEG)-based signatures and neuromodulation approaches. The cholinergic hypothesis, rooted in degeneration of basal forebrain projections and cortical cholinergic deficits, remains clinically relevant¹⁴: It underpins the symptomatic efficacy of acetylcholinesterase inhibitors and highlights the need to preserve synaptic communication, not only to remove aggregated proteins.

At the same time, there is growing interest in the gut–brain axis and the influence of the intestinal microbiome. Alterations in microbial composition, increased intestinal permeability, and the interaction of microbial metabolites with the immune and nervous systems may trigger chronic inflammation and modify neuroimmune responses. Similar importance is attributed to metabolic dysregulation (e.g., insulin resistance), cerebral hypoxia, mitochondrial dysfunction, and epigenetic modifications.

New diagnostic tools: Biomarkers, EEG, and neuroimaging

One of the greatest challenges in AD diagnostics is detecting the disease at a very early, preclinical stage. In this context, so-called liquid biomarkers are particularly promising – including microRNAs (miRNAs), plasma neurodegenerative proteins, and indicators of inflammation and neuronal injury. MiRNAs, as stable regulatory molecules found in serum, saliva, and cerebrospinal fluid, have demonstrated both diagnostic and predictive potential.¹⁵

These molecular data are complemented by non-invasive functional methods such as EEG – especially the analysis of theta and alpha activity – which can detect subtle disruptions in neural network dynamics. When combined with advanced neuroimaging techniques (positron emission tomography [PET], structural and functional magnetic resonance imaging [MRI]), it becomes possible to develop integrated diagnostic algorithms that may one day support risk prediction and treatment response monitoring.

Increasing importance is also attributed to clinical observation and digital behavioral biomarkers. A striking example is progressive loss of smell (anosmia) and hearing (hypoacusis), which – according to several studies – may occur 10–15 years before the onset of cognitive symptoms in AD.¹⁶ This phenomenon is thought to reflect early pathological changes in the olfactory bulb and temporal cortex. However, its diagnostic value has been complicated in recent years by the COVID-19 pandemic,

which has caused transient or persistent anosmia in millions of people worldwide, reducing the specificity of this symptom as a prodromal marker.

In parallel, artificial intelligence algorithms are being developed to analyze facial expressions and emotional responses in patients – e.g., during clinical interviews or video recordings. Preliminary research suggests that subtle alterations in facial dynamics – such as delayed emotional reactivity, facial asymmetry, or diminished expressiveness – may be detectable even in early prodromal phases.¹⁷ This opens up the possibility of a low-cost, non-invasive screening tool applicable in outpatient or home-based settings.

Multimodal therapies: Beyond conventional pharmacology

Given the complexity of AD pathogenesis, there is a growing consensus among experts on the need to move away from the “one target – one drug” paradigm. Multimodal therapies, which combine multiple mechanisms of action, are increasingly recognized as more appropriate for the biological and clinical reality of AD. Such an approach includes targeting neuroinflammation, oxidative stress, cellular metabolism, protein aggregation, cognitive function, and neuroplasticity simultaneously.

Examples include experimental hydrophobic peptides that inhibit the aggregation of β -amyloid or tau protein without triggering immune responses.¹⁸ Other strategies encompass transcranial direct current stimulation (tDCS), electromagnetic stimulation, or optogenetics, which can modulate synaptic plasticity and cortical activity in memory-related regions.¹⁹ Nutraceutical interventions – particularly those based on polyphenols, curcumin, melatonin, and omega-3 fatty acids – also show promise due to their anti-inflammatory, antioxidant, and neuroprotective properties.²⁰

However, these therapies require further translational research, standardized protocols, and long-term monitoring of safety and efficacy across diverse age and genetic populations.^{17–20}

Ethics, safety, and transparency in research

As increasingly advanced experimental therapies, particularly immunological and molecular approaches, are introduced, ethical considerations become more crucial. Patients with mild cognitive impairment may have limited ability to fully comprehend the risks associated with participating in clinical trials, especially invasive ones.²¹ It is therefore essential to implement informed consent procedures that are precise, empathetic, and cognitively appropriate.²²

Moreover, the reporting of results – in both scientific publications and public media – must adhere to the highest standards of transparency. Misleading language (e.g., “breakthrough,” “Alzheimer’s cure”) can lead to misinformation and unrealistic public expectations. This underscores the growing need for independent platforms for therapy assessment, ethical oversight mechanisms, and international standards for drug approval and monitoring.²³

Looking ahead: An integrated model for treatment and prevention

A modern approach to AD requires a strategic shift toward integrating knowledge from multiple levels of biology and medicine. Increasing evidence suggests that effective treatment must address multiple pathophysiological mechanisms simultaneously, while also accounting for individual patient characteristics – genetic, environmental, and psychosocial.²⁴ In this context, multi-omics analysis, machine learning, and artificial intelligence-based predictive technologies play a crucial role.^{25,26}

Such an integrated approach enables not only the precise tailoring of therapy to a patient’s biological profile but also the development of effective prevention strategies. Lifestyle modifications (diet, physical activity, sleep), metabolic and neurocognitive prevention, and health education are essential components of a modern public health strategy for AD.²⁴

Conclusion: Time for a paradigm shift

Alzheimer’s disease is not merely a medical challenge – it is also a test for contemporary science, ethics, and healthcare systems. Clinging to a single dominant model of pathogenesis, despite repeated therapeutic failures, risks cognitive stagnation and costly strategic missteps. The time has come to acknowledge the limitations of the current paradigm and boldly embrace integrative, multidisciplinary, and personalized models. Only through the synergy of biological, technological, and social knowledge can we realistically hope to improve the quality of life for millions of patients and their families.

Use of AI and AI-assisted technologies

Not applicable.

ORCID iDs

Benita Wiatrak  <https://orcid.org/0000-0002-1404-2274>

Adam Szeląg  <https://orcid.org/0000-0001-8104-5267>

References

1. World Health Organization (WHO). Dementia. Geneva, Switzerland: World Health Organization (WHO); 2025. <https://www.who.int/news-room/fact-sheets/detail/dementia>.
2. Alzheimer’s Disease International. World Alzheimer Report 2024. Global changes in attitudes to dementia. London, UK: Alzheimer’s Disease International: The International Federation of Alzheimer’s Disease and Related Disorders Societies, Inc.; 2024. <https://www.alzint.org/u/World-Alzheimer-Report-2024.pdf>.
3. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*. 2020;396(10248):413–446. doi:10.1016/S0140-6736(20)30367-6
4. Liu W, Deng W, Gong X, Ou J, Yu S, Chen S. Global burden of Alzheimer’s disease and other dementias in adults aged 65 years and over, and health inequality related to SDI, 1990–2021: Analysis of data from GBD 2021. *BMC Public Health*. 2025;25(1):1256. doi:10.1186/s12889-025-22378-z
5. Cummings JL. Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer’s disease: Strategies and research directions. *Neurotherapeutics*. 2025;22(3):e00570. doi:10.1016/j.neurot.2025.e00570
6. Wang H, Pan J, Zhang M, Tan Z. Re-evaluation of the efficacy and safety of anti-A β monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer’s disease. *Front Pharmacol*. 2025; 16:1599048. doi:10.3389/fphar.2025.1599048
7. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. *EMBO Mol Med*. 2016;8(6):595–608. doi:10.15252/emmm.201606210
8. Long JM, Holtzman DM. Alzheimer disease: An update on pathobiology and treatment strategies. *Cell*. 2019;179(2):312–339. doi:10.1016/j.cell.2019.09.001
9. Price JL, Morris JC. Tangles and plaques in nondemented aging and preclinical Alzheimer’s disease. *Ann Neurol*. 1999;45(3):358–368. doi:10.1002/1531-8249(199903)45:3%3C358::AID-ANA12%3E3.0.CO;2-X
10. Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. *Alzheimers Dement*. 2021; 17(4):696–701. doi:10.1002/alz.12213
11. Mudher A, Colin M, Dujardin S, et al. What is the evidence that tau pathology spreads through prion-like propagation? *Acta Neuropathol Commun*. 2017;5(1):99. doi:10.1186/s40478-017-0488-7
12. Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: A longitudinal study. *JAMA Neurol*. 2019;76(8):915. doi:10.1001/jamaneurol.2019.1424
13. Wiatrak B, Piasny J, Kuźniarski A, Gąsiorowski K. Interactions of amyloid- β with membrane proteins. *Int J Mol Sci*. 2021;22(11):6075. doi:10.3390/ijms22116075
14. Hampel H, Mesulam MM, Cuello AC, et al. Revisiting the cholinergic hypothesis in Alzheimer’s disease: Emerging evidence from translational and clinical research. *J Prev Alzheimers Dis*. 2019;6(1):2–15. doi:10.14283/jpad.2018.43
15. Leidinger P, Backes C, Deutscher S, et al. A blood based 12-miRNA signature of Alzheimer disease patients. *Genome Biol*. 2013;14(7):R78. doi:10.1186/gb-2013-14-7-r78
16. Silva MDME, Mercer PBS, Witt MCZ, Pessoa RR. Olfactory dysfunction in Alzheimer’s disease: Systematic review and meta-analysis. *Dement Neuropsychol*. 2018;12(2):123–132. doi:10.1590/1980-57642018dn12-020004
17. Takeshige-Amano H, Oyama G, Ogawa M, et al. Digital detection of Alzheimer’s disease using smiles and conversations with a chatbot. *Sci Rep*. 2024;14(1):26309. doi:10.1038/s41598-024-77220-0
18. Gutierrez-Merino C. Anti-amyloid β hydrophobic peptides in Alzheimer’s disease: Biomarkers and therapeutic potential. *Explor Neurosci*. 2025;4:100672. doi:10.37349/en.2025.100672
19. Chen J, Wang Z, Chen Q, Fu Y, Zheng K. Transcranial direct current stimulation enhances cognitive function in patients with mild cognitive impairment and early/mid Alzheimer’s disease: A systematic review and meta-analysis. *Brain Sci*. 2022;12(5):562. doi:10.3390/brainsci12050562

20. Gupta S, Shenoy A, Chaudhari V, Buttar HS, Chintamaneni M, Kaur G. Therapeutic roles of antioxidant and nutraceuticals in the prevention and management of Alzheimer's disease: A systematic review. *Biomed Rev*. 2021;32:1–29. <https://journals.mu-varna.bg/index.php/bmr/article/download/8496/7497>.
21. Kim SYH. The ethics of informed consent in Alzheimer disease research. *Nat Rev Neurol*. 2011;7(7):410–414. doi:10.1038/nrneurol.2011.76
22. Götzelmann TG, Strech D, Kahrass H. The full spectrum of ethical issues in dementia research: Findings of a systematic qualitative review. *BMC Med Ethics*. 2021;22(1):32. doi:10.1186/s12910-020-00572-5
23. Hrinco V, Roy KT, Robillard JM. Practical social media recommendations for dementia prevention researchers. *Alzheimers Dement (NY)*. 2024;10(3):e12496. doi:10.1002/trc2.12496
24. Zhao C, Noble JM, Marder K, Hartman JS, Gu Y, Scarmeas N. Dietary patterns, physical activity, sleep, and risk for dementia and cognitive decline. *Curr Nutr Rep*. 2018;7(4):335–345. doi:10.1007/s13668-018-0247-9
25. Lin S, Zhan Y, Wang R, Pei J. Decoding neuroinflammation in Alzheimer's disease: A multi-omics and AI-driven perspective for precision medicine. *Front Immunol*. 2025;16:1616899. doi:10.3389/fimmu.2025.1616899
26. Rudroff T, Rainio O, Klén R. AI for the prediction of early stages of Alzheimer's disease from neuroimaging biomarkers: A narrative review of a growing field. *Neurol Sci*. 2024;45(11):5117–5127. doi:10.1007/s10072-024-07649-8